ZIMVIE INC Stock Price, News & Analysis

ZimVie Inc. (Nasdaq: ZIMV) announces that Highmark and BCBS North Dakota have deemed the Tether™ device as medically necessary for treating pediatric scoliosis. Effective January 30, 2023, and March 6, 2023, respectively, the new policies expand eligibility for vertebral body tethering (VBT) to over 4 million and 280,000 patients. The Tether™ is the only FDA-approved device for VBT, with over 1,300 applications since its humanitarian device exemption in August 2019. Experts indicate these developments highlight advancements in VBT technology, allowing more children to access crucial treatment within their growth window.

ZimVie Inc. (Nasdaq: ZIMV) reported its FY 2022 financial results, with third-party net sales of $909.5 million, reflecting a 9.8% decline compared to FY 2021. The company recorded a net loss of ($63.9 million) and a net loss margin of (7.0%). Adjusted net income rose to $47.9 million with adjusted diluted EPS at $1.84. The fourth quarter saw net sales of $228.2 million, down 12.4% year-over-year. Key developments included new product launches, an expanded policy decision affecting 4+ million lives, and a successful ERP transition. Guidance for FY 2023 predicts net sales between $825 million and $850 million.

ZimVie Inc. (Nasdaq: ZIMV) announced advancements in its digital dentistry platform with the launch of two new modules: the RealGUIDE CAD and FULL SUITE. The CAD module enhances restorative workflows with advanced design capabilities, allowing users to create complex dental structures easily. The FULL SUITE integrates existing modules into a comprehensive system, facilitating collaborative implant planning and guided surgery. These innovations will debut at LMT Lab Day in Chicago and expand to Europe at the International Dental Show next month. This strategic enhancement aims to streamline operations for dental practices and support successful patient outcomes.

ZimVie Inc. (Nasdaq: ZIMV) announced it will report its financial results for the fourth quarter and full year 2022 on March 1, 2023, after market close. A conference call will follow at 4:30 p.m. Eastern Time. Interested parties can register for the call. ZimVie specializes in dental and spine markets and became an independent entity in March 2022, focusing on its product portfolio to serve customers in over 70 countries.

ZimVie Inc. (Nasdaq: ZIMV) announced a significant milestone, with over 200,000 Mobi-C Cervical Discs implanted globally since its FDA approval in 2013 for cervical disc replacement. This achievement aligns with the ten-year anniversary of the device's FDA clearance, which marked its superiority over fusion surgeries at the seven-year mark, and continued patient-reported outcomes at ten years. ZimVie highlights this success as part of its 'Year of Mobi-C' initiative, reinforcing its commitment to advancing cervical disc technology and improving patient care.

ZimVie Inc. (Nasdaq: ZIMV), a leader in life sciences within the dental and spine markets, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Vafa Jamali is scheduled to speak on January 11, 2023, at 3:00 p.m. PT. The presentation will be accessible via a live and archived webcast. Founded in March 2022 as a spin-off from Zimmer Biomet, ZimVie provides a wide range of dental and spine solutions across over 70 countries, focusing on product innovation and clinical evidence.

ZimVie Inc. (Nasdaq: ZIMV) reported third quarter 2022 financial results with third party net sales of $213.3 million, a decrease of 10.6% year-over-year. Net income reached $0.8 million, compared to a net loss of $30.2 million in Q3 2021. Adjusted diluted EPS was $0.49. The dental segment saw a slight decline of 3.9%, while the spine segment dropped 16.4%, influenced by market exits and competitive pressures. Cash reserves were $116.0 million. The company reaffirmed full-year guidance for net sales of $915 to $930 million and adjusted EPS of $1.80 to $2.00.

ZimVie has launched the TSX Implant, a significant innovation in its dental solutions portfolio. Designed for immediate extraction and loading, the TSX Implant aims to enhance peri-implant health and improve placement predictability in various bone types. This implant integrates over 20 years of clinical data, emphasizing features that promote long-term osseointegration and stability. The implant was recently introduced at the American Academy of Periodontology’s annual meeting, showcasing ZimVie’s commitment to advancing digital dental workflows and improving patient outcomes.

ZimVie Inc. (Nasdaq: ZIMV) will announce its third quarter 2022 financial results on November 9, 2022, after market close. Following the results, the management will conduct a conference call at 4:30 p.m. Eastern Time. Interested participants can register online and are encouraged to do so at least 15 minutes prior to the call. ZimVie specializes in dental and spine markets, providing a range of products for various spine pathologies and dental procedures. The company became an independent entity in March 2022, focusing on strategic growth in its sectors.